Leerink Partners analyst David Risinger has reiterated their bullish stance on BMY stock, giving a Buy rating on January 12.Invest with ...

Analyst Terence Flynn of Morgan Stanley maintained a Sell rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target of ...

The stocks in the S&P 500, for instance, average a yield of just 1.3%. It would mean you have to invest around $77,000 in S&P 500 stocks to expect to collect just $1,000 in dividends over the course ...

We recently compiled a list of the 15 Stocks to Invest in with Steady Dividends. In this article, we are going to take a look ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

The pharma giant is paying $110 million up front to begin the collaboration. Bristol Myers Squibb’s Cobenfy treats schizophrenia by going after a different target than currently available ...

Could the largest market for the new schizophrenia drug xanomeline and trospium chloride (Cobenfy) be in Alzheimer's disease ...

Bristol-Myers Squibb's $14 billion bet on buying Karuna ... trospium chloride – formerly known as KarXT – under the Cobenfy brand name for the treatment of schizophrenia in adults.

The FDA also gave its nod to Bristol Myers Squibb’s Cobenfy (xanomeline and trospium chloride), the first new class of antischizophrenia drug to be approved in decades. Roughly one-third of last ...

that looks set to benefit Bristol-Myers Squibb, which ended a 10-year hiatus in new-mechanism therapies for the disorder when it got FDA approval for Cobenfy (xanomeline tartrate/trospium chloride ...

said US pharma major Bristol Myers Squibb (NYSE: BMY). “The results from our long-term trials further support the differentiated profile of Cobenfy and reinforce prior findings of robust and ...